Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Highlights ► Adults ≥40 years of age are commonly hypo-responsive to licensed HBV vaccines. ► HBsAg-1018 ISS elicits earlier, higher and longer lasting antibody than Engerix-B . ► 2 doses of HBsAg-1018 ISS provides superior protection over 3 doses of Engerix-B . ► HBsAg-1018 ISS was well tolerated w...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-03, Vol.30 (16), p.2689-2696
Main Authors: Sablan, Benjamin P, Kim, Dong Joon, Barzaga, Nina G, Chow, Wan Cheng, Cho, Mong, Ahn, Sang Hoon, Hwang, Seong Gyu, Lee, Ji Hyun, Namini, Hamid, Heyward, William L
Format: Article
Language:English
Subjects:
Adjuvants
Adjuvants, Immunologic
Adult
Aged
Allergy and Immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Antigens
Combined vaccines
Diabetes
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Female
Geriatrics
Hemodialysis
Hepatitis
Hepatitis B
Hepatitis B - immunology
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B surface antigen
Hepatitis B Surface Antigens - genetics
Hepatitis B Surface Antigens - immunology
Hepatitis B vaccine
Hepatitis B Vaccines - adverse effects
Hepatitis B Vaccines - genetics
Hepatitis B Vaccines - immunology
Hepatitis B virus
Hepatitis B virus - immunology
Humans
Immunity, Humoral
Immunostimulation
Infections
Kidney diseases
Licenses
Male
Middle Aged
Older adults
Oligodeoxyribonucleotides - genetics
Oligodeoxyribonucleotides - immunology
Pain
Placebos
Seroprotection
Toll-Like Receptor 9 - agonists
Toll-Like Receptor 9 - genetics
Toll-Like Receptor 9 - immunology
Toll-like receptors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► Adults ≥40 years of age are commonly hypo-responsive to licensed HBV vaccines. ► HBsAg-1018 ISS elicits earlier, higher and longer lasting antibody than Engerix-B . ► 2 doses of HBsAg-1018 ISS provides superior protection over 3 doses of Engerix-B . ► HBsAg-1018 ISS was well tolerated with a similar safety profile as Engerix-B . ► HBsAg-1018 ISS may be more effective in hypo-responsive populations.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.02.001